Treatment of Severe Hepatic Steatosis
Lifestyle Interventions
- The American Association for the Study of Liver Diseases recommends achieving sustained weight loss of at least 7-10% through dietary modification and exercise, with Mediterranean-style dietary patterns and at least 150 minutes weekly of moderate-intensity physical activity being the most strongly recommended interventions 1, 2
- Aim for >10% sustained weight reduction to improve fibrosis in patients with severe steatosis, particularly those with overweight or obesity 1, 3
- Weight loss of 5% reduces liver fat 1
- Weight loss of 7-10% improves liver inflammation 1, 2
- Adopt a Mediterranean dietary pattern including vegetables, fruits, unsweetened high-fiber cereals, nuts, fish or white meat, and olive oil 1, 2, 4
- Eliminate sugar-sweetened beverages completely 1, 2
- Limit ultra-processed foods rich in sugars and saturated fat 1, 2
- Prescribe at least 150 minutes per week of moderate-intensity exercise or 75 minutes per week of vigorous-intensity activity 1, 2, 5
- Physical activity reduces steatosis even without significant weight loss 1, 4
Pharmacological Considerations
- Resmetirom should be considered for non-cirrhotic patients with significant liver fibrosis (stage ≥2) if approved locally, as it demonstrated histological efficacy in phase III trials with acceptable safety 6, 7, 8
- GLP-1 receptor agonists (semaglutide, liraglutide) should be used for their approved indications (type 2 diabetes, obesity) as they improve cardiometabolic outcomes and are safe in MASH, including compensated cirrhosis 7, 8, 5, 4
- Statins are safe and should be used for dyslipidemia in patients with hepatic steatosis 4, 9
Monitoring and Risk Stratification
- Stratify patients using FIB-4 score, liver stiffness measurement (LSM), or liver biopsy 4
- High-risk patients have FIB-4 >2.67, LSM >12.0 kPa, or significant fibrosis on biopsy 4
- Patients with advanced fibrosis (F3) require hepatocellular carcinoma surveillance with imaging every 6 months 9
Multidisciplinary Approach
- A multidisciplinary approach is essential to address both liver-related and extrahepatic outcomes, given the bidirectional connections between steatotic liver disease and cardiometabolic comorbidities 2, 3
- Screen and manage diabetes, dyslipidemia, and hypertension aggressively 4
- Optimize glycemic control in diabetic patients to reduce liver fat 4
- Avoid medications that worsen steatosis including corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid 4
Special Considerations
- Consider bariatric surgery for appropriate individuals with clinically significant fibrosis and obesity with comorbidities 4
- Coffee consumption has been associated with improvements in liver damage and reduced liver-related clinical outcomes in observational studies 1, 2, 5
- Weight loss through diet and exercise remains the only intervention with Level 1 evidence for improving liver injury 1, 2, 3